Neuropeptide Y polymorphism increases the risk for asthma in overweight subjects; protection from atherosclerosis in asthmatic subjects – The cardiovascular risk in young Finns study

[1]  T. Danielsson,et al.  Obesity and Cardiovascular Disease , 2006, Obesity Prevention and Treatment.

[2]  T. Wynn,et al.  Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.

[3]  O. Raitakari,et al.  Inflammatory effects of blood leukocytes: association with vascular function in neuropeptide Y proline 7-genotyped type 2 diabetes patients , 2011, Diabetes & vascular disease research.

[4]  O. Raitakari,et al.  The Leu7Pro polymorphism of the signal peptide of neuropeptide Y (NPY) gene is associated with increased levels of inflammatory markers preceding vascular complications in patients with type 2 diabetes. , 2010, Microvascular research.

[5]  M. Masrizal.  OBESITY AND CARDIOVASCULAR DISEASE IN CHILDREN , 2010 .

[6]  S. Kasayama,et al.  Reduced carotid atherosclerosis in asthmatic patients treated with inhaled corticosteroids , 2010, European Respiratory Journal.

[7]  L. Tan,et al.  Neuropeptide Y polymorphisms and ischemic stroke in Chinese population. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[8]  O. Bang,et al.  Association of the C-399T promoter polymorphism of neuropeptide Y with susceptibility to ischemic stroke. , 2009, Clinical biochemistry.

[9]  G. Hansson.  Inflammatory mechanisms in atherosclerosis , 2009, Journal of thrombosis and haemostasis : JTH.

[10]  C. Lavie,et al.  Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. , 2009, Journal of the American College of Cardiology.

[11]  P. Finn,et al.  Innate immunity and asthma. , 2009, Proceedings of the American Thoracic Society.

[12]  L. Keltikangas-Järvinen,et al.  Metabolic syndrome and short‐term heart rate variability in young adults , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[13]  W. Kraus,et al.  Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis , 2009, PLoS genetics.

[14]  P. Ramamoorthy,et al.  A Common Single Nucleotide Polymorphism Alters the Synthesis and Secretion of Neuropeptide Y , 2008, The Journal of Neuroscience.

[15]  Risto Telama,et al.  Cohort profile: the cardiovascular risk in Young Finns Study. , 2008, International journal of epidemiology.

[16]  E. Toledo,et al.  Association between obesity and asthma among teenagers. , 2008, Sao Paulo medical journal = Revista paulista de medicina.

[17]  A. Linneberg,et al.  Association of obesity and insulin resistance with asthma and aeroallergen sensitization , 2008, Allergy.

[18]  Ahmad R. Hariri,et al.  Genetic variation in human NPY expression affects stress response and emotion , 2008, Nature.

[19]  V. Vaccarino,et al.  Adult-onset asthma is associated with increased carotid atherosclerosis among women in the Atherosclerosis Risk in Communities (ARIC) study. , 2007, Atherosclerosis.

[20]  V. Backer,et al.  Association between obesity and asthma in a twin cohort , 2007, Allergy.

[21]  Herbert Herzog,et al.  NPY and receptors in immune and inflammatory diseases. , 2007, Current topics in medicinal chemistry.

[22]  F. Sallee,et al.  Relevance of neuropeptide Y (NPY) in psychiatry. , 2007, Current topics in medicinal chemistry.

[23]  R. Devereux,et al.  Prognostic Impact of Metabolic Syndrome by Different Definitions in a Population With High Prevalence of Obesity and Diabetes , 2007, Diabetes Care.

[24]  J. Pogue,et al.  Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. , 2007, European heart journal.

[25]  Lydia E. Kuo,et al.  Stress, NPY and vascular remodeling: Implications for stress-related diseases , 2007, Peptides.

[26]  D. Umetsu,et al.  The regulation of allergy and asthma , 2006, Immunological reviews.

[27]  G. Bray,et al.  Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[28]  L. Steinman,et al.  A neuropeptide in immune-mediated inflammation, Y? , 2006, Trends in immunology.

[29]  W. Poewe,et al.  Allergic rhinitis, asthma, and atherosclerosis in the Bruneck and ARMY studies. , 2005, Archives of internal medicine.

[30]  A. Folsom,et al.  Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities Study , 2005, Thorax.

[31]  M. Koulu,et al.  The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression, and increased cardiovascular responsiveness to norepinephrine during oral glucose tolerance test. , 2005, The Journal of clinical endocrinology and metabolism.

[32]  A. Hubbard,et al.  Polymorphisms in Ghrelin and Neuropeptide Y Genes Are Associated with Non-Hodgkin Lymphoma , 2005, Cancer Epidemiology Biomarkers & Prevention.

[33]  B. Forsberg,et al.  Obesity increases the risk of incident asthma among adults , 2005, European Respiratory Journal.

[34]  J. Viikari,et al.  Interrelations Between Brachial Endothelial Function and Carotid Intima-Media Thickness in Young Adults: The Cardiovascular Risk in Young Finns Study , 2004, Circulation.

[35]  L. Niskanen,et al.  Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women. , 2004, Bone.

[36]  K. Chung,et al.  Neuropeptide Y (NPY). , 2004, Pulmonary pharmacology & therapeutics.

[37]  T. Hedner,et al.  Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population , 2004, Journal of hypertension.

[38]  P. Ducimetiere,et al.  Bronchial Hyperresponsiveness to Methacholine Is Associated With Increased Common Carotid Intima-Media Thickness in Men , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[39]  N. Kohno,et al.  Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. , 2004, Diabetes research and clinical practice.

[40]  D. Dockery,et al.  Body‐mass index as a predictor of incident asthma in a prospective cohort of children , 2003, Pediatric pulmonology.

[41]  T. Laitinen,et al.  Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. , 2003, JAMA.

[42]  O. Axelson,et al.  High body mass index, asthma and allergy in Swedish schoolchildren participating in the International Study of Asthma and Allergies in Childhood: Phase II , 2003, Acta paediatrica.

[43]  M. Koulu,et al.  Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. , 2003, The Journal of clinical endocrinology and metabolism.

[44]  F. Pralong,et al.  Neuropeptide Y: the universal soldier , 2003, Cellular and Molecular Life Sciences CMLS.

[45]  Duanping Liao,et al.  Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. , 2002, Diabetes.

[46]  F. Lombardi.  Clinical implications of present physiological understanding of HRV components. , 2002, Cardiac electrophysiology review.

[47]  M. Koulu,et al.  Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. , 2001, Atherosclerosis.

[48]  R. Pabst,et al.  Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes , 2001, Journal of Neuroimmunology.

[49]  M. Koulu,et al.  Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  T. Jartti.  Asthma, asthma medication and autonomic nervous system dysfunction. , 2001, Clinical physiology.

[51]  A. Kastin.  What is a neuropeptide? , 2000, Trends in Neurosciences.

[52]  L. Edvinsson,et al.  Vasodilation in human subcutaneous arteries induced by neuropeptide Y is mediated by neuropeptide Y Y1 receptors and is nitric oxide dependent , 2000 .

[53]  L. Niskanen,et al.  Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels , 1998, Nature Medicine.

[54]  D. Smith,et al.  Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells , 1998, Diabetologia.

[55]  M. Levite.  Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Su,et al.  Interleukin 18 stimulates HIV type 1 in monocytic cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  H. Kleinman,et al.  Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. , 1998, Circulation research.

[58]  M. Michel,et al.  Renal effects of neuropeptide Y , 1998, Pflügers Archiv.

[59]  T. Kuusela,et al.  Cardiovascular autonomic regulation in asthmatic children evidenced by spectral analysis of heart rate and blood pressure variability. , 1996, Scandinavian journal of clinical and laboratory investigation.

[60]  J. Goodfellow,et al.  Non-invasive detection of endothelial dysfunction , 1996, The Lancet.

[61]  A. Malliani,et al.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use , 1996 .

[62]  Z. Żukowska-Grójec.  Neuropeptide Y , 1995, Annals of the New York Academy of Sciences.

[63]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[64]  S. Jain,et al.  Clinical dysautonomia in patients with bronchial asthma. Study with seven autonomic function tests. , 1990, Chest.

[65]  R. Kerwin,et al.  CORONARY ARTERY INFUSION OF NEUROPEPTIDE Y IN PATIENTS WITH ANGINA PECTORIS , 1987, The Lancet.

[66]  J. Okuda,et al.  Inhibition of glucose-stimulated insulin release by pseudo-alpha-DL-glucose as a glucokinase inhibitor. , 1985, Biochemistry international.

[67]  H. Sasaki,et al.  Bronchial hyperresponsiveness to methacholine after exercise in asthmatics. , 1985, Annals of allergy.

[68]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[69]  R. Weston,et al.  LUNG CANCER AND SMOKING IN SWITZERLAND. , 1965, Lancet.

[70]  L. Bouter,et al.  Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study , 2009, European Journal of Clinical Nutrition.

[71]  N. Eller,et al.  Heart rate variability and intima media thickness , 2006, International journal of behavioral medicine.

[72]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[73]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[74]  L. Niskanen,et al.  Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[75]  M. Koulu,et al.  Neuropeptide Y polymorphism and alcohol consumption in middle-aged men. , 2000, American journal of medical genetics.